---
document_datetime: 2024-10-11 08:42:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/kentera-epar-all-authorised-presentations_en.pdf
document_name: kentera-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7992975
conversion_datetime: 2025-12-31 04:30:36.080548
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength    | Pharmaceutical form   | Route of administration   | Immediate Packaging                   | Pack size              |
|------------------|-------------------|-------------|-----------------------|---------------------------|---------------------------------------|------------------------|
| EU/1/03/270/001  | Kentera           | 3.9 mg/24 h | Transdermal patch     | Transdermal use           | sachet (PA/PE/alu/PET/paper laminate) | 8 transdermal patches  |
| EU/1/03/270/002  | Kentera           | 3.9 mg/24 h | Transdermal patch     | Transdermal use           | sachet (PA/PE/alu/PET/paper laminate) | 24 transdermal patches |
| EU/1/03/270/003  | Kentera           | 3.9 mg/24 h | Transdermal patch     | Transdermal use           | sachet (PA/PE/alu/PET/paper laminate) | 2 transdermal patches  |